BRIP1 and Cancer Risk: What the Evidence Supports

What BRIP1 Does

BRIP1 (also called FANCJ or BACH1) is a DNA helicase that unwinds DNA structures during repair. It interacts directly with BRCA1 and supports homologous recombination and the resolution of stalled replication forks.

Biallelic loss of BRIP1 causes a form of Fanconi anaemia, a recessive condition with bone-marrow failure and cancer predisposition, which is distinct from the risk carried by a single pathogenic variant.

Ovarian Cancer Risk

Large case-control studies have found that heterozygous loss-of-function BRIP1 variants are associated with an increased risk of epithelial ovarian cancer, with estimates commonly in the range of a two- to threefold relative increase, translating to a moderate absolute lifetime risk.

This is enough that many guidelines discuss risk-reducing salpingo-oophorectomy for carriers, typically at an older age than for BRCA1 carriers.

The Weaker Breast Cancer Signal

BRIP1 was initially proposed as a breast cancer gene, but subsequent large studies did not confirm a clinically important association. Current consensus is that pathogenic BRIP1 variants are not established breast cancer risk genes.

This shift illustrates why early reports based on small samples should be treated cautiously until replicated.

Variant Classification Matters

The risk data apply to clearly loss-of-function variants such as nonsense and frameshift changes. Missense variants are frequently classified as uncertain, and a BRIP1 variant of uncertain significance does not establish risk.

Laboratories update classifications as evidence accumulates, so the report date and the classifying laboratory are worth keeping.

Interpretation Notes

A BRIP1 result should be interpreted through clinical genetics, with personal and family history factored in, rather than from the gene name alone.

Whether BRIP1 loss predicts benefit from PARP inhibitors is not well established and should not be assumed from its BRCA1 partnership.

Key Takeaways

• ·BRIP1 is a BRCA1-associated DNA helicase; biallelic loss causes Fanconi anaemia.
• ·Heterozygous loss-of-function variants raise ovarian cancer risk moderately.
• ·A clinically important breast cancer association has not been confirmed.
• ·A BRIP1 variant of uncertain significance is not a risk result.